Nanoparticles are a dendritic cells-targeted delivery strategy and carrier platform used to improve the stability, uptake, and controlled release of biologics. They function by optimizing physicochemical properties for passive targeting, enhancing dendritic-cell uptake, and stabilizing payloads such as antigens and adjuvants for better presentation and immune activation. In cancer vaccines, they can act as both carriers and adjuvants, supporting targeted delivery and improved antigen/adjuvant stability. They are also listed among CRISPR-Cas delivery approaches, highlighting their broader role in precision biotechnology. Recent literature emphasizes lipid-based nanoparticle formulations for dendritic-cell targeting and delivery technologies for cancer vaccines, including a 2026 Journal of Controlled Release review (PMID:41812866) and a 2026 Bioactive Materials article (PMID:41756688).
Delivery and Immunotherapy
- Nanoparticle platforms are optimized for passive targeting and uptake by dendritic cells, with physicochemical tuning used to improve delivery performance. (PMID:41812866)
- In cancer vaccines, nanoparticles enhance antigen stability and presentation efficiency, supporting more effective immune priming. (PMID:41756688)
- Nanoparticles can stabilize adjuvants and function as either carriers or adjuvants themselves, broadening their immunologic utility. (PMID:41756688)
- A 2026 review on delivery technologies for cancer vaccines highlighted nanoparticle-enabled controlled release and targeted delivery as key design features. (PMID:41756688)
CRISPR-Cas Delivery
- Nanoparticles are included among CRISPR-Cas delivery strategies, reflecting their role as a nonviral platform for precision biotechnology. (PMID:41987615)
- A 2026 review of CRISPR-Cas delivery approaches placed nanoparticles within the broader landscape of delivery systems used to enable genome-editing applications. (PMID:41987615)